Related references
Note: Only part of the references are listed.Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas
Florian Gessler et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor
Florian Gessler et al.
WORLD NEUROSURGERY (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy
Roland Roelz et al.
SCIENTIFIC REPORTS (2016)
Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma
Matthew M. Grabowski et al.
JOURNAL OF NEUROSURGERY (2014)
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Jason Beiko et al.
NEURO-ONCOLOGY (2014)
Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy
F. -W. Kreth et al.
ANNALS OF ONCOLOGY (2013)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas
Asgeir S. Jakola et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion
Walter Stummer et al.
ACTA NEUROCHIRURGICA (2011)
Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
An extent of resection threshold for newly diagnosed glioblastomas
Nader Sanai et al.
JOURNAL OF NEUROSURGERY (2011)
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial
Christian Senft et al.
LANCET ONCOLOGY (2011)
Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
David Capper et al.
BRAIN PATHOLOGY (2010)
Intraobserver and Interobserver Agreement in Volumetric Assessment of Glioblastoma Multiforme Resection
Pieter L. Kubben et al.
NEUROSURGERY (2010)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Independent association of extent of resection with survival in patients with malignant brain astrocytoma
Matthew J. McGirt et al.
JOURNAL OF NEUROSURGERY (2009)
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
et al.
NEUROSURGERY (2009)
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Justin S. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Thierry Gorlia et al.
LANCET ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Long-term survival with glioblastoma multiforme
Dietmar Krex et al.
BRAIN (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme
Ramon Martinez et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
W Stummer et al.
LANCET ONCOLOGY (2006)
Concordance probability and discriminatory power in proportional hazards regression
M Gönen et al.
BIOMETRIKA (2005)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas
Y Okamoto et al.
ACTA NEUROPATHOLOGICA (2004)
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
ER Laws et al.
JOURNAL OF NEUROSURGERY (2003)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
M Lacroix et al.
JOURNAL OF NEUROSURGERY (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
